Joyce O'Shaughnessy, MD
Medical Oncology · Dallas, TXNPI 1790727709
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $900,903 of the $1,343,729 with a category attached, or 67.0%. It is spread thinly across 48 manufacturers, the largest accounting for just 16.1%. Reporting peaked in 2023 at $321,923 and has fallen 58.8% since, to $132,490 in 2025. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 857 payments — averaging $1567.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$216K
- Merck$189K
- Seagen Inc.$108K
- AstraZeneca$103K
- Astrazeneca UK Limited$92K
- Pfizer$84K
- plus $551K from 42 others
Across 4,045 payments — averaging $4828.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.1M
- Merck$3.9M
- Genentech, Inc.$2M
- AstraZeneca$2M
- Eli Lilly$1.7M
- Pharmacyclics LLC, An Abbvie Company$1.2M
- plus $4.7M from 24 others
What the payments were for
- Consulting fees$900,90367%
- Speaking & faculty fees$285,72121%
- Grants$3500%
- Travel & lodging$141,02310%
- Food & beverage$11,2921%
- Education$8260%
- Other$3,6140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,343,729 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 80 | $1,103,390 |
| IbrancePalbociclib | 33 | $502,722 |
| Anastrozole | 552 | $11,122 |
| XareltoRivaroxaban | 13 | $10,068 |
| Letrozole | 430 | $9,514 |
| ZarxioFilgrastim-Sndz | 12 | $5,941 |
| Exemestane | 23 | $2,912 |
| Duloxetine Hcl | 70 | $1,713 |
| Estradiol | 17 | $1,559 |
| Escitalopram Oxalate | 68 | $819 |
| Bupropion XlBupropion Hcl | 22 | $805 |
| Potassium Chloride | 63 | $689 |
| Trazodone Hcl | 100 | $566 |
| Tamoxifen Citrate | 33 | $565 |
| Pantoprazole Sodium | 21 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $216,144 | $1,103,743107 claims |
| PfizerIbrance | $83,895 | $502,72233 claims |
| SandozZarxio | $7,500 | $5,94112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
- Kartik KonduriDallas$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.